On March 30, 2023 at 13:08:53 ET an unusually large
$534.73K block of Call contracts in Bristol-Myers Squibb
(BMY) was bought,
with a strike price of $65.00 / share, expiring in 659 days (on January 17, 2025).
Fintel tracks all large options trades, and the premium spent on this trade was 4.44 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in BMY options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 21.31% Upside
As of March 30, 2023,
the average one-year price target for Bristol-Myers Squibb is $82.71.
The forecasts range from a low of $62.62 to a high of $99.75.
The average price target represents an increase of 21.31% from its latest reported closing price of $68.18.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Bristol-Myers Squibb
is $47,586MM, an increase of 3.09%.
The projected annual non-GAAP EPS
is $8.03.
What is the Fund Sentiment?
There are 3931 funds or institutions reporting positions in Bristol-Myers Squibb.
This is an increase
of
111
owner(s) or 2.91% in the last quarter.
Average portfolio weight of all funds dedicated to BMY is 0.59%,
a decrease
of 15.58%.
Total shares owned by institutions decreased
in the last three months by 1.50% to 1,846,900K shares.
The put/call ratio of BMY is 0.74, indicating a
bullish
outlook.
What are Large Shareholders Doing?
Jpmorgan Chase &
holds 98,663K shares
representing 4.69% ownership of the company.
No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 64,633K shares
representing 3.07% ownership of the company.
In it’s prior filing, the firm reported owning 63,698K shares, representing
an increase
of 1.45%.
The firm
decreased
its portfolio allocation in BMY by 5.16% over the last quarter.
Capital International Investors
holds 52,717K shares
representing 2.51% ownership of the company.
In it’s prior filing, the firm reported owning 52,396K shares, representing
an increase
of 0.61%.
The firm
decreased
its portfolio allocation in BMY by 6.29% over the last quarter.
VFINX – Vanguard 500 Index Fund Investor Shares
holds 49,151K shares
representing 2.34% ownership of the company.
In it’s prior filing, the firm reported owning 48,404K shares, representing
an increase
of 1.52%.
The firm
decreased
its portfolio allocation in BMY by 5.32% over the last quarter.
Bank Of America
holds 40,126K shares
representing 1.91% ownership of the company.
In it’s prior filing, the firm reported owning 45,188K shares, representing
a decrease
of 12.61%.
The firm
decreased
its portfolio allocation in BMY by 99.91% over the last quarter.
Bristol-Myers Squibb Declares $0.57 Dividend
On March 3, 2023 the company declared a regular
quarterly dividend of $0.57 per share ($2.28 annualized).
Shareholders of record as of April 10, 2023
will receive the payment on May 1, 2023.
Previously, the company paid $0.57 per share.
At the current share price of $68.18 / share,
the stock’s dividend yield is 3.34%.
Looking back five years and taking a sample every week, the average dividend yield has been
3.08%,
the lowest has been 2.54%,
and the highest has been 3.88%.
The standard deviation of yields is 0.26 (n=236).
The current dividend yield is
1.04 standard deviations
above
the historical average.
Additionally, the company’s dividend payout ratio is 0.76.
The payout ratio tells us how much of a company’s income is paid out in dividends. A payout ratio of one (1.0)
means 100% of the company’s income is paid in a dividend.
A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend – not a
healthy situation.
Companies with few growth prospects are expected to pay out most of their income in dividends, which typically
means a payout ratio between 0.5 and 1.0.
Companies with good growth prospects are expected to retain some earnings in order to invest
in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company’s 3-Year dividend growth rate is 0.27%,
demonstrating that it has increased its dividend over time.
Bristol-Myers Squibb Background Information
(This description is provided by the company.)
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
